Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

2C-D

From PsychonautWiki Archive
Revision as of 14:18, 20 January 2016 by >Oskykins (effect::Geometry)
Jump to navigation Jump to search

Template:Proofread

2C-D
Chemical Nomenclature
Common names 2C-D, 2C-M, LE-25
Substitutive name 2,5-Dimethoxy-4-methylphenethylamine
Systematic name 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminoethane
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 3 mg
Light 10 - 25 mg
Common 25 - 50 mg
Strong 50 - 100 mg
Heavy 100 mg +
Duration
Total 3 - 5 hours
Onset 15 - 45 minutes
Come up 20 - 40 minutes
Peak 1.5 - 2.5 hours
Offset 0.5 - 1.5 hours
After effects 1 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Summary sheet: 2C-D

2C-D (2,5-dimethoxy-4-methylphenethylamine, also known as 2C-M) is a phenethylamine psychedelic drug of the 2C-x family that is sometimes used as an entheogen. It was first synthesized in 1970 by a team from the Texas Research Institute of Mental Sciences,[1] and its activity was subsequently investigated in humans by Alexander Shulgin[2]. The full name of the chemical is 2,5-dimethoxy-4-methylphenethylamine. In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin lists the dosage range as being from 20 to 60 mg and many people recommend higher doses. Lower doses (generally 10 mg or less) of 2C-D have been explored as a potential nootropic, albeit with mixed results. 2C-D is generally taken orally, though may be insufflated (i.e., taken nasally). Insufflating tends to cause intense pain, however, and the dosage level is usually much lower, typically in the region of 1 to 15 mg.

Not much information is known about the toxicity of 2C-D, as no major studies have been conducted. According to Shulgin, the effects of 2C-D typically last for 4–6 hours. Shulgin himself referred to this substance as a “pharmacological tofu,” meaning that when mixed with other substances, it can extend or potentiate their effects without coloring the experience too much, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with. Some people have claimed 2C-D is relatively uninteresting on its own, but many other users have strongly disagreed with this assessment and believe that 2C-D is a true psychedelic in its own right.

In modern times, it is used as a recreational drug and an entheogen, rarely sold on the streets and almost exclusively obtained as a grey area research chemical through the use of online vendors. Therefore, it is relatively uncommon and has only a short history of human use.

Many users report that 2C-D is calmer and much more sedating than other closely related psychedelic phenethylamines.

Chemistry

General formula of phenethylamine molecule.

2C-D or 2,5-dimethoxy-4-methylphenethylamine is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-D contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4 of the phenyl ring. 2C-D belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.[2]

Pharmacology

2C-D's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

Cognitive effects

The head space of 2C-D is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages. The feeling of "unaltered consciousness" may be bothersome to trippers that are willing to experience events and concepts from a shifting point of view, since on 2C-D everything is fairly normal, stable and therefore rather uninteresting.

The total sum of these cognitive components regardless of the setting generally includes:

Visual effects

Enhancements

Distortions

The visual geometry that is present throughout this trip can be described as more similar in appearance to that of DOM or 25D-NBOMe than that of LSD, 2C-B or 2C-I. They can be comprehensively described as structured in their organization, organic in style, intricate in complexity, large in size, slow and smooth in motion, colourful in scheme, bright in colour, blurred in its edges and equally rounded and angular in its corners. They give off a natural feel at higher dosages. Whilst the final level of 2C-D geometry 2C-D has yet to be formally confirmed, it seems more likely that it would result in states of Level 8B visual geometry over Level 8A.

Hallucinatory states

Auditory effects

Toxicity and harm potential

The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-D is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychedelic community who have tried 2C-D suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Tolerance and addiction potential

2C-D is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 2C-D are built almost immediately after ingestion. After that it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). Note that 2C-D presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 2C-D all psychedelics will have a reduced effect.

  • United States: 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.[3]
  • United Kingdom: 2C-D is a Class A controlled substance as it is covered by the phenethylamine derivatives clause of the Misuse of Drugs Act of 1971.
  • Sweden: 2C-D is classified as a "health hazard" as of March 1, 2005 in their regulation SFS 2005:26, making it illegal to sell or possess.[4]
  • Japan: 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell. [5]
  • Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.[6]
  • Denmark: 2C-D is added to the list of Schedule B controlled substances.[7]
  • Germany: On December, 13 2014 2C-D was added to the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.[8]

See also

References

  1. Amphetamine analogs. II. Methylated phenethylamines | https://www.ncbi.nlm.nih.gov/pubmed/5412084
  2. 2.0 2.1 2,5-Dimethoxy-4-chlorophenethylamine (IsomerDesign / PiHKAL) http://isomerdesign.com/PiHKAL/read.php?id=22
  3. S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs | http://www.govtrack.us/congress/bills/112/s3187/text
  4. Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
  5. Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical AŠairs Law in Japan, Part I: GC-MS and LC-MS | https://www.erowid.org/references/texts/show/7395docid7635
  6. New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New%20Psychoactive%20Substances.pdf
  7. Bekendtgørelse om euforiserende stoffer | https://www.retsinformation.dk/Forms/R0710.aspx?id=137169
  8. Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (28. BtMÄndV)| http://www.buzer.de/gesetz/11392/a189949.htm